
A zzso zzso Phase I and pharmacological study of the zzso synthesis inhibitor SAM zzso was zzso A dosing regimen of four weekly infusions followed by 2 weeks off therapy was zzso Fifty patients were entered into the zzso zzso levels studied were zzso zzso 5, 8, 16, 32, 48, 70, zzso zzso zzso and 325 zzso zzso sampling was done on day 1, and trough samples were taken weekly during the first treatment zzso zzso sampling was done on days 1 and zzso At 325 zzso zzso toxicity was seen (one patient each with grade 4 zzso zzso grade 3 zzso and grade 3 zzso with zzso and zzso zzso on zzso The recommended dose for further testing was set at zzso zzso zzso time was increased from 10 to 180 zzso due to facial zzso and zzso and zzso Drug exposure increased zzso with zzso Mean zzso zzso zzso at zzso zzso doses was zzso zzso with a large volume of distribution at steady zzso In peripheral blood zzso a clear relationship between dose and zzso effect on zzso zzso or changes in zzso zzso pools was not zzso SAM zzso can be administered safely using a dosing regimen of four weekly infusions followed by 2 weeks off zzso The recommended dose for Phase II studies using this regimen is zzso zzso 

